Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future

References

• Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396–403. doi:10.1016/j.ijid.2020.06.099
   PubMed Web of Science ®Google Scholar
• Ghazy RM, Almaghraby A, Shaaban R, et al. A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. Sci Rep. 2020;10(1):22139. doi:10.1038/s41598-020-77748-x
   PubMed Web of Science ®Google Scholar
• Self WH, Semler MW, Leither LM, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with covid-19: a randomized clinical trial. JAMA. 2020;324(21):2165–2176. doi:10.1001/jama.2020.22240
   PubMed Web of Science ®Google Scholar
• Reis G, Moreira Silva E, Medeiros Silva DC, et al. Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial. JAMA Netw Open. 2021;4(4):e216468. doi:10.1001/jamanetworkopen.2021.6468
   PubMed Web of Science ®Google Scholar
• Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383:2030–2040.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517–525. doi:10.1056/NEJMoa2016638
   PubMed Web of Science ®Google Scholar
• Sutanto H, Heijman J. Beta-adrenergic receptor stimulation modulates the cellular proarrhythmic effects of chloroquine and azithromycin. Front Physiol. 2020;11:587709. doi:10.3389/fphys.2020.587709
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799. doi:10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Horby P, Mafham M, Bell L, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–1352. doi:10.1016/S0140-6736(20)32013-4
   PubMed Web of Science ®Google Scholar
• Lopez-Medina E, Lopez P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021;325(14):1426. doi:10.1001/jama.2021.3071
   PubMed Web of Science ®Google Scholar
• Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter -J-J. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID Nineteen Study. Chest. 2021;159(1):85–92. doi:10.1016/j.chest.2020.10.009
   PubMed Web of Science ®Google Scholar
• Solaymani-Dodaran M, Ghanei M, Bagheri M, et al. Safety and efficacy of favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol. 2021;95:107522. doi:10.1016/j.intimp.2021.107522
   PubMed Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an Open-Label Control Study. Engineering. 2020;6:1192–1198.
   Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826. doi:10.1056/NEJMoa2007764
   PubMed Web of Science ®Google Scholar
• Garibaldi BT, Wang K, Robinson ML, et al. Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19. JAMA Netw Open. 2021;4(3):e213071. doi:10.1001/jamanetworkopen.2021.3071
   PubMed Web of Science ®Google Scholar
• Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708. doi:10.3389/fimmu.2020.01708
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, June CH, Longo DL. Cytokine storm. N Engl J Med. 2020;383(23):2255–2273. doi:10.1056/NEJMra2026131
   PubMed Web of Science ®Google Scholar
• Bonam SR, Kaveri SV, Sakuntabhai A, Gilardin L, Bayry J. Adjunct immunotherapies for the management of severely Ill COVID-19 patients. Cell Rep Med. 2020;1(2):100016. doi:10.1016/j.xcrm.2020.100016
   PubMedGoogle Scholar
• Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients. J Infect. 2021;82(3):329–338. doi:10.1016/j.jinf.2021.01.022
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Kawase M, Nao N, et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells. J Virol. 2020;95:e01648–20.
   PubMed Web of Science ®Google Scholar
• Chatterjee K, Wu C-P, Bhardwaj A, Siuba M. Steroids in COVID-19: an overview. Cleve Clin J Med. 2020. doi:10.3949/ccjm.87a.ccc059
   PubMedGoogle Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704.
   PubMed Web of Science ®Google Scholar
• Villar J, Anon JM, Ferrando C, et al. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial. Trials. 2020;21(1):717. doi:10.1186/s13063-020-04643-1
   PubMed Web of Science ®Google Scholar
• Petersen MW, Meyhoff TS, Helleberg M, et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiol Scand. 2020;64:1365–1375. doi:10.1111/aas.13673
   PubMed Web of Science ®Google Scholar
• Tomazini BM, Maia IS, Cavalcanti AB, et al.; Investigators CC-BI. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307–1316. doi:10.1001/jama.2020.17021
   PubMed Web of Science ®Google Scholar
• Dequin P-F, Heming N, Meziani F, et al.; Group CCT, the C-TN. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(13):1298–1306. doi:10.1001/jama.2020.16761
   PubMed Web of Science ®Google Scholar
• Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317–1329. doi:10.1001/jama.2020.17022
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Murthy S, Diaz JV, et al.; Group WHOREAfC-TW. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–1341. doi:10.1001/jama.2020.17023
   PubMed Web of Science ®Google Scholar
• Li Q, Li W, Jin Y, et al. Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: a Retrospective Cohort Study. Infect Dis Ther. 2020;9(4):823–836. doi:10.1007/s40121-020-00332-3
   PubMed Web of Science ®Google Scholar
• Spagnuolo V, Guffanti M, Galli L, et al., group CO-Bs. Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. Sci Rep. 2020;10(1):21291. doi:10.1038/s41598-020-78039-1
   PubMedGoogle Scholar
• Cavalli G, Larcher A, Tomelleri A, et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021;3(4):e253–e261. doi:10.1016/S2665-9913(21)00012-6
   PubMedGoogle Scholar
• Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384:1491–1502.
   PubMed Web of Science ®Google Scholar
• Abani O, Abbas A, Abbas F, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645.
   PubMed Web of Science ®Google Scholar
• Khan FA, Stewart I, Fabbri L, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021;thoraxjnl-2020-215266. doi:10.1136/thoraxjnl-2020-215266
   Web of Science ®Google Scholar
• Wei Q, Lin H, Wei RG, et al. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10:71. doi:10.1186/s40249-021-00857-w
   PubMed Web of Science ®Google Scholar
• Rosas IO, Brau N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503–1516. doi:10.1056/NEJMoa2028700
   PubMed Web of Science ®Google Scholar
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al.; Investigators BBTT. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383:2333–2344. doi:10.1056/NEJMoa2028836
   PubMed Web of Science ®Google Scholar
• Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30. doi:10.1056/NEJMoa2030340
   PubMed Web of Science ®Google Scholar
• Weisberg E, Parent A, Yang PL, et al. Repurposing of kinase inhibitors for treatment of COVID-19. Pharm Res. 2020;37(9):167. doi:10.1007/s11095-020-02851-7
   PubMed Web of Science ®Google Scholar
• Zhao H, Mendenhall M, Deininger MW. Imatinib is not a potent anti-SARS-CoV-2 drug. Leukemia. 2020;34(11):3085–3087. doi:10.1038/s41375-020-01045-9
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi:10.1016/j.clim.2020.108393
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al.; Members A-SG. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795–807. doi:10.1056/NEJMoa2031994
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Lenfant T, Calabrese C. Interferon therapy for COVID-19 and emerging infections: prospects and concerns. Cleve Clin J Med. 2020. doi:10.3949/ccjm.87a.ccc066
   Google Scholar
• Zhou Q, Chen V, Shannon CP, et al. Interferon-alpha2b treatment for COVID-19. Front Immunol. 2020;11:1061. doi:10.3389/fimmu.2020.01061
   PubMed Web of Science ®Google Scholar
• Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon beta-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64. doi:10.1128/AAC.01061-20
   PubMed Web of Science ®Google Scholar
• Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2021;384:497–511.
   PubMed Web of Science ®Google Scholar
• Lee JS, Shin E-C. The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. 2020;20(10):585–586. doi:10.1038/s41577-020-00429-3
   PubMed Web of Science ®Google Scholar
• Nguyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS, McDonald DR. Immunoglobulins in the treatment of COVID-19 infection: proceed with caution! Clin Immunol. 2020;216:108459. doi:10.1016/j.clim.2020.108459
   PubMed Web of Science ®Google Scholar
• Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020;26:1708–1713. doi:10.1038/s41591-020-1088-9
   PubMed Web of Science ®Google Scholar
• Jeyaraman P, Agrawal N, Bhargava R, et al. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies. Transfus Apher Sci. 2021;60(3):103075. doi:10.1016/j.transci.2021.103075
   PubMed Web of Science ®Google Scholar
• Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Zuriaga-Alvaro A, Group RC. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397:2049–2059.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label Phase II multicentre randomised controlled trial (PLACID trial). BMJ. 2020;371:m3939. doi:10.1136/bmj.m3939
   PubMed Web of Science ®Google Scholar
• Simonovich VA, Burgos Pratx LD, Scibona P, et al.; PlasmAr Study G. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384:619–629. doi:10.1056/NEJMoa2031304
   PubMed Web of Science ®Google Scholar
• Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021;325:1185–1195. doi:10.1001/jama.2021.2747
   PubMed Web of Science ®Google Scholar
• Biernat MM, Kolasinska A, Kwiatkowski J, et al. Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID-19. Viruses. 2021;13:436.
   PubMed Web of Science ®Google Scholar
• Hueso T, Pouderoux C, Pere H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136:2290–2295. doi:10.1182/blood.2020008423
   PubMed Web of Science ®Google Scholar
• Bayry J, Misra N, Latry V, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003;10:165–169. doi:10.1016/S1246-7820(03)00035-1
   PubMed Web of Science ®Google Scholar
• Galeotti C, Kaveri SV, Bayry J. Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19). Clin Transl Immunol. 2020;9(10):e1198. doi:10.1002/cti2.1198
   PubMed Web of Science ®Google Scholar
• Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi S-R, Hajizadeh R. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis. 2020;20(1):786. doi:10.1186/s12879-020-05507-4
   PubMed Web of Science ®Google Scholar
• Cao W, Liu X, Hong K, et al. High-dose intravenous immunoglobulin in severe coronavirus disease 2019: a Multicenter Retrospective Study in China. Front Immunol. 2021;12:627844. doi:10.3389/fimmu.2021.627844
   PubMed Web of Science ®Google Scholar
• WHO. COVID-19 Clinical Management: Living Guidance. World Health Organization; 2021.
   Google Scholar
• Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372:n579. doi:10.1136/bmj.n579
   PubMed Web of Science ®Google Scholar
• Robinson PC, Richards D, Tanner HL, Feldmann M. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol. 2020;2(11):e653–e655. doi:10.1016/S2665-9913(20)30309-X
   PubMedGoogle Scholar
• Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159:481–491 e483. doi:10.1053/j.gastro.2020.05.032
   PubMed Web of Science ®Google Scholar
• Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. doi:10.1136/annrheumdis-2020-217871
   PubMed Web of Science ®Google Scholar
• Gao T, Hu M, Zhang X, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv. 2020;2020.
   Google Scholar
• Risitano AM, Mastellos DC, Huber-Lang M, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20(6):343–344. doi:10.1038/s41577-020-0320-7
   PubMed Web of Science ®Google Scholar
• Esmaeilzadeh A, Elahi R. Immunobiology and immunotherapy of COVID-19: a clinically updated overview. J Cell Physiol. 2021;236(4):2519–2543. doi:10.1002/jcp.30076
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Fisk M, Kostapanos M, et al. Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-arm therapeutic study in pre-ICu patients admitted with Covid-19 – repurposed drugs (TACTIC-R): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):626. doi:10.1186/s13063-020-04535-4
   PubMed Web of Science ®Google Scholar
• Onomoto K, Onoguchi K, Yoneyama M. Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors. Cell Mol Immunol. 2021;18:539–555.
   PubMed Web of Science ®Google Scholar
• Rodrigues TS, de Sa KSG, Ishimoto AY, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2021;218(3). doi:10.1084/jem.20201707
   PubMed Web of Science ®Google Scholar
• Toldo S, Bussani R, Nuzzi V, et al. Inflammasome formation in the lungs of patients with fatal COVID-19. Inflamm Res. 2021;70(1):7–10. doi:10.1007/s00011-020-01413-2
   PubMed Web of Science ®Google Scholar
• Harrell CR, Jovicic BP, Djonov V, Volarevic V, Amantini C. Therapeutic potential of mesenchymal stem cells and their secretome in the treatment of SARS-CoV-2-induced acute respiratory distress syndrome. Anal Cell Pathol. 2020;2020:1939768. doi:10.1155/2020/1939768
   Web of Science ®Google Scholar